Clinical trials: insulin glargine
Diabetes Mellitus, Type I
Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs
The aim of this study is to evaluate the variations in pharmacokinetic and pharmacodynamic properties of rapid-acting insulin analogs when given as a bolus by subcutaneous insulin infusion pump as typically encountered in the…
- Trial name
- PK/PD (NCT00652288)
- Testing
- Insulin analogs (Lispro and Aspart), Insulin analogs (Aspart and Detemir), Insulin analogs (Lispro and Glargine)
- Volunteers
- 36 people
- Sponsor
- Yale University
Diabetes Mellitus, Type 2
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
The purpose of this study is to compare the change in glycemic control, as measured by hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin glulisine as mealtime insulin following a variable bolus…
- Trial name
- NCT00135057
- Testing
- insulin glulisine, insulin glargine
- Where
- United States
- Volunteers
- 281 people
- Sponsor
- Sanofi
Type 2 Diabetes
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then…
- Trial name
- NCT03336528
- Testing
- Degludec, Glargine, Aspart
- Where
- 4 sites in United States
- Volunteers
- 180 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe).
- Trial name
- NCT03751657
- Testing
- Insulin icodec, Metformin, Dipeptidyl peptidase-4 inhibitors
- Where
- 49 sites in United States, Canada and 5 more
- Volunteers
- 247 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes.
- Trial name
- SWITCH PRO (NCT03687827)
- Testing
- Insulin degludec, Insulin glargine
- Where
- 67 sites in United States, Canada and 4 more
- Volunteers
- 498 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes
This study is comparing the effect of a long-acting insulin analogue (insulin 287) with insulin glargine (Lantus®) in subjects with type 2 diabetes.
- Trial name
- NCT03945656
- Testing
- insulin icodec, Insulin glargine
- Where
- Austria
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
The study aims to evaluate arterial stiffness and endothelial function indexes and their relationship with clinic and laboratory varible in a group of diabetic patients in treatment with dulaglutide
- Trial name
- NCT03824002
- Testing
- Dulaglutide, Aspart insulin, Glargine
- Where
- Italy
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Diabetes Mellitus, Type 2
Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients
Primary Objective: To investigate the impact of insulin glargine versus Neutral Protamine Hagedorn basal insulin on a composite diabetes related quality of life score (DRQoL).
- Trial name
- NCT00941369
- Testing
- Insulin Glargine (HOE901)/NPH Insulin
- Where
- Germany
- Volunteers
- 345 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
Primary objectives : To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus…
- Trial name
- OSIRIS (NCT00174642)
- Testing
- Insulin Glargine, Insulin Glulisine, Metformin
- Where
- 18 sites in Belgium, France and 16 more
- Volunteers
- 811 people
- Sponsor
- Sanofi
Type 2 Diabetes
Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes
Glucose-induced insulin secretion is often diminished in hyperglycaemic patients with type 2 diabetes. The investigators examined, whether chronic basal insulin treatment with insulin glargine lead to improvements in…
- Trial name
- NCT01249677
- Testing
- insulin glargine
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Ruhr University of Bochum
Pre-diabetes
Study TO Prevent Diabetes With Short-term Insulin Glargine Only
Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as well as macrovascular and microvascular complication.
- Trial name
- STOP-GO (NCT01276912)
- Testing
- Insulin glargine, Lifestyle counseling
- Where
- China
- Volunteers
- 2,420 people
- Sponsor
- Beijing Tongren Hospital
Type 2 Diabetes
The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
Gastric emptying is now recognized as a major determinant of the blood glucose response to carbohydrate in both health and type 2 diabetes (T2D).
- Trial name
- NCT05284344
- Testing
- Anti-Diabetics
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Adelaide
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate a novel approach for insulin glargine (LY2963016) titration for insulin-naïve adults with type 2 diabetes (T2D) The study will last about 6 months.
- Trial name
- NCT04864977
- Testing
- Basal Insulin
- Where
- United States
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT00982644)
- Testing
- insulin degludec, insulin glargine
- Where
- 187 sites in United States, Austria and 13 more
- Volunteers
- 1,030 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01374178
- Testing
- LY2963016, Lantus
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04957914
- Testing
- Insulin Glargine, LY3209590
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin
At present, one of the reasons for the low blood sugar control rate in China is related to the late use of basic insulin and insufficient dose adjustment.
- Trial name
- NCT04553380
- Testing
- basic insulin
- Volunteers
- 150 people
- Sponsor
- Shenzhen Second People's Hospital
Type1diabetes, Fasting
Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan
To compare different timing of insulin Glargine administration (early-6 pm versus standard bedtime-10 pm) as part of standard of care in patients with type1 diabetes who wish to fast the month of Ramadan.
- Conditions
- Type1diabetes, Fasting, Insulin
- Trial name
- NCT04383990
- Testing
- Timing of taking insulin
- Where
- Saudi Arabia
- Volunteers
- 185 people
- Sponsor
- King Abdullah International Medical Research Center
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of biphasic insulin aspart 30 once daily compared to insulin glargine once daily both in combination with metformin…
- Trial name
- EasyMix (NCT01123980)
- Testing
- biphasic insulin aspart 30, metformin, glimepiride
- Where
- 34 sites in China, Japan
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Hyperglycemia
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is…
- Trial name
- SITA-CABGDM (NCT02556918)
- Testing
- Sitagliptin, Regular Human Insulin, Insulin glargine
- Where
- 3 sites in United States
- Volunteers
- 202 people
- Sponsor
- Emory University